Pancreatic Cancer Trial, Recruiting NCT06164769 Sponsor: Zhejiang University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06164769
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a non-cancerous or low-risk tumour of the pancreas (such as pancreatic neuroendocrine tumours, solid pseudopapillary tumours, or cystadenomas) that has not spread to nearby blood vessels or other parts of the body
  • People whose tumour is located in a specific part of the pancreas called the head, neck, or uncinate process (the lower front section of the pancreas)
  • People whose surgery involves blocking two specific blood vessels — the abdominal trunk and the superior mesenteric artery — during a keyhole (laparoscopic) procedure to remove the tumour

Who may not be able to join:

  • People who have a highly aggressive or cancerous pancreatic tumour, or a tumour that has grown into surrounding tissue or spread to other parts of the body
  • People whose tumour is located in the body or tail (the middle or left side) of the pancreas
  • People whose surgery needs to be converted to a different type of operation, such as a larger keyhole procedure (laparoscopic pancreaticoduodenectomy) or open surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bo Zhou, Dr., The Second Affiliated Hospital, Zhejiang Chinese Medical University

Phone: +86-13957161680

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Zhejiang University
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
30 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

blood loss

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov